The EGFR-mTOR pathway and laryngeal cancer angiogenesis

European Archives of Oto-Rhino-Laryngology

Volumn 271, Issue 4, 2014, Pages 757-764

  Lionello, Marco ^a   Lovato, A ^a   Staffieri, A ^a   Blandamura, S ^a   Turato, C ^a   Giacomelli, L ^a   Staffieri, C ^a   Marioni, G ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Angiogenesis; CD105; EGFR; Laryngeal carcinoma; mTOR; Prognosis

Indexed keywords

ENDOGLIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL DENSITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE FREE SURVIVAL; DISTANT METASTASIS; ECHOGRAPHY; ENDOTHELIUM CELL; ESOPHAGOSCOPY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LARYNGEAL BIOPSY; LARYNGECTOMY; LARYNX SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROLARYNGOSCOPY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; SIGNAL TRANSDUCTION; THORAX RADIOGRAPHY; TREATMENT DURATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84897856264     PISSN: 09374477     EISSN: 14344726     Source Type: Journal    
DOI: 10.1007/s00405-013-2691-x     Document Type: Article

References (36)

1. Marioni G (2012) Letter to the editors: essentials for an updated epidemiology of laryngeal carcinoma. Cancer Treat Rev 38:559
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
3. Carpenter G (1983) The biochemistry and physiology of the receptor-kinase for epidermal growth factor. Mol Cell Endocrinol 31:1-19
4. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369-385 (Pubitemid 44142736)
5. Loganathan S, Kandala PK, Gupta P, Srivastava SK (2012) Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model. PLoS ONE 7:e43577
6. Abraham RT, Eng CH (2008) Mammalian target of rapamycin as a therapeutic target in oncology. Expert Opin Ther Targets 12:209-222 (Pubitemid 351284963)
7. Don AS, Zheng XF (2011) Recent clinical trials of mTOR-targeted cancer therapies. Rev Recent Clin Trials 6:24-35
8. Lionello M, Staffieri A, Marioni G (2012) Potential prognostic and therapeutic role for angiogenesis markers in laryngeal carcinoma. Acta Otolaryngol 132:574-582
9. Weidner N (1993) Tumour angiogenesis: review of current applications in tumour prognostication. Sem Diagn Pathol 10:302-313
10. Nachtigal P, Zemankova Vecerova L, Rathouska J, Strasky Z (2012) The role of endoglin in atherosclerosis. Atherosclerosis 224:4-11
11. Tanaka F, Ishikawa S, Yanagihara K et al (2002) Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 62:7124-7129 (Pubitemid 35424109)
12. Sobin LH, Gospodarowicz MK, Wittekind C (eds) (2009) TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, Oxford
13. Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A (2006) Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 32:504-515 (Pubitemid 44488046)
14. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
15. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: eGFR gene and cancer. FEBS J 277:301-308
16. Numico G, Franco P, Cristofano A et al (2013) Is the combination of cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit Rev Oncol Hematol 85:112-120
17. Prince A, Aguirre-Ghizo J, Genden E, Posner M, Sikora A (2010) Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med 77:684-699
18. Pfister DG, Ang KK, Brizel D et al (2011) NCCN practice guidelines in oncology, head and neck cancers, version 2.2011. National Comprehensive Cancer Network
19. Bozec A, Peyrade F, Milano G (2013) Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives. Anticancer Agents Med Chem 13:389-402
20. Marioni G, Staffieri A, Giacomelli L et al (2011) Mammalian target of rapamycin expression and laryngeal squamous cell carcinoma prognosis: novel preliminary evidence. Histopathology 58:1148-1156
21. Marioni G, Staffieri A, Lora L et al (2012) mTOR expression and prognosis in elderly patients with laryngeal carcinoma: uni- and multivariate analyses. Oral Oncol 48:530-534
22. Lionello M, Blandamura S, Loreggian L et al (2012) High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: a pilot study. J Oral Pathol Med 41:136-140
23. Dionysopoulos D, Pavlakis K, Kotoula V et al (2013) Cyclin D1, EGFR, and Akt/mTOR pathway: potential prognostic markers in localized laryngeal squamous cell carcinoma. Strahlenther Onkol 189:202-215
24. Marioni G, Marino F, Giacomelli L et al (2006) Endoglin expression is associated with poor oncologic outcome in oral and oropharyngeal carcinoma. Acta Otolaryngol 126:633-639 (Pubitemid 43995216)
25. Marioni G, Marino F, Blandamura S et al (2010) Neoangiogenesis in laryngeal carcinoma: angiogenin and CD105 expression is related to carcinoma recurrence rate and disease-free survival. Histopathology 57:535-543
26. Marioni G, Blandamura S, Loreggian L et al (2011) Laryngeal carcinoma prognosis after postoperative radiotherapy correlates with CD105 expression, but not with angiogenin or EGFR expression. Eur Arch Otorhinolaryngol 268:1779-1787
27. Fujita D, Tanabe A, Sekijima T et al (2010) Role of extracellular signal-regulated kinase and AKT cascades in regulating hypoxia-induced angiogenic factors produced by a trophoblast-derived cell line. J Endocrinol 206:131-140
28. Lei FR, Li XQ, Liu H, Zhu RD, Meng QY, Rong JJ (2012) Rapamycin and 3-methyladenine regulate apoptosis and autophagy in bone-derived endothelial progenitor cells. Chin Med J (Engl) 125:4076-4082
29. Walpen T, Kalus I, Schwaller J, Peier MA, Battegay EJ, Humar R (2012) Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation. Biochem Biophys Res Commun 429:24-30
30. Bajaj A, Li QF, Zheng Q, Pumiglia K (2012) Loss of NF1 expression in human endothelial cells promotes autonomous proliferation and altered vascular morphogenesis. PLoS ONE 7:e49222
31. Rodon J, Dienstmann R, Serra V, Tabernero J (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10:143-153
32. Phung TL, Ziv K, Dabydeen D et al (2006) Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10:159-170 (Pubitemid 44175906)
33. Ponnurangam S, Standing D, Rangarajan P, Subramaniam D (2013) Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth. Mol Cancer Ther 12:598-609
34. Li GY, Jung KH, Lee H et al (2013) A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway. Cancer Lett 329:59-67
35. Dazert E, Hall MN (2011) mTOR signaling in disease. Curr Opin Cell Biol 23:744-755
36. James R, Vishwakarma S, Chivukula IV et al (2012) EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs. Cancer Med 1:114-127